Bioequivalency Study of Two Formulations of Ketoconazole Tablet in Healthy Volunteers Bioequivalenecy of ketoconazole tablets
Iranian Journal of Pharmaceutical Sciences,
Vol. 1 Núm. 4 (2005),
1 October 2005
,
Página 209-215
https://doi.org/10.22037/ijps.v1.39539
Resumen
In this study, the pharmacokinetic parameters of two marketed tablet formulations of ketoconazole were studied, and the relative bioavailability of the test formulation was compared with a reference formulation. A single dose (12x2) double blind randomized cross-over study of a generic formulation of ketoconazole tablet (2x200 mg), and a commercial brand, Nizoral tablet (2x200 mg, Janssen Pharmaceutica
Beerse Belgica) was carried out. All of the tablets met the United States Pharmacopoeia dissolution specifications. The plasma level of ketoconazole was determined by using a modified rapid and selective reverse phase HPLC method. Plasma data was used to evaluate the relative bioavailability and other pharmacokinetic parameters characterizing rate [peak plasma concentration (Cmax) and time of peak concentration (Tmax)] and the extent of absorption (AUC). The mean peak plasma concentration (Cmax) of ketoconazole of the two different formulations, A (reference) and B (test), were 7.08±2.81 and 6.74±2.20 mg/l at 1.70±0.48 h and 1.73±0.75 h, respectively. The mean AUC0− ∞ of the two products, were 39.07±16.25 and 31.85±14.64 for Aand B, respectively. Statistical analysis showed no significant d i fferences between various pharmacokinetic parameters of the two different formulations. The 90% parametric confidence intervals for the mean of test/reference ratios of Cmax, AUC0- 12,AUC0−∞ and Cmax/AUC0−∞ were within the bioequivalence acceptable range (80-125%). Results of this study showed that the extent and rate of absorption of ketoconazole tablets tested are comparable and the generic formulation is bioequivalent to the commercial product.
- Bioequivalence
- Ketoconazole
- Pharmacokinetic parameters
Cómo citar
Citas
[2] Parfitt K. Martindale, the extra pharmacopoie. 33th ed. vol. 1, London: The Pharmaceutical Press, 2002; pp. 389-90.
[3] Daneshmand TK, Wornock DW. Clinical pharmacokinetics of ketoconazole. Clin Pharmacokin 1988; 14: 13-34.
[4] Drug facts and comparisons. 58th ed. Missouri: Fact and Comparisons Inc., 2004; 1564-5.
[5] Gennoro AR, Chase GD. Remington: the science and practice of pharmacy. 20th ed. Pennsylvania: Mack Publishing Company, 2000; 1552-3.
[6] Physicians’ desk reference, PDR. 58th ed., NJ: Medical Economics Company, 2004; 1757-9.
[7] Scheifele DW, Hunter MI, Bortolussi RA. Ketoconazole. Can Med Assoc J 1985; 133: 1117- 20.
[8] Skelly JP, Van Burskirk GA, Savello DR, Amindon Gl, Arbit HM, Dighes, Fawzi MB, Gonzalez MA, Malick AW, Malinowski H, Nedich R, Peck GE, Pearce DM, Shah V, Shangraw RF, Schwartz JB, Truelove J. Workshop
report, scale-up of immediate release oral solid dosage forms. Pharm Res 1993; 10: 313-6.
[9] Immediate release solid oral dosage forms; scaleup and postapproval changes: chemistry, manufacturing and controls: in vitro dissolution testing; in vivo bioequivalence documentation guidance. Fed Reg 1995; 60: 61638-43.
[10] Schroeder TJ, Cho MJ, Pollack GM, Floc’h R, Moran HB, Levy R, Moore LW, Pouletty P. Comparison of two cyclosporine formulations in healthy volunteers: Bioequivalence of the new Sang-35 formulation and Neoral. J Clin Pharmacol 1998; 38: 807-14.
[11] Shah A, Liu MC, Vaughan D, Heller AH. Oral bioequivalence of three ciprofloxacin formulations following single-dose administration: 500 mg tablet compared with 500 mg/10 mL or 500 mg/5 mL suspension and the effect of food on the absorption of ciprofloxacin oral suspension. J Antimicrob Chemother 1999; 43 (Suppl. A): 49-54.
[12] Foroutan SM, Shafaati AR, Zarghi A, Khoddam A. Bioequivalence studies of two formulations of baclofen tablet in healthy volunteers. Iranian J Pharm Res 2003; 2: 153-5.
[13] S h a rgel L, Yu A. Applied biopharmaceutics an d pharmacokinetics. 4th ed., Appleton and Lange, 1999; pp. 247-79.
[14] The united state pharmacopoeia, U.S.P. 26 and N. F. 21. vol.1 and 2, Rockville: United state pharmacopoeia convention, 2003; pp. 1046-8, 2155- 6.
[15] Chin TWF, Loeb M, Fong IW. Effects of an acidic beverage (Coca-Cola) on absorption of ketoconazole. Antimicrob Agents Chemother 1995; 39: 671-5.
[16] Boroujerdi M. Pharmacokinetics. New York: McGraw-Hill, 2002; pp. 153-80.
[17] Cartwright AC. International harmonization and consensus DIA meeting on bioavailability testing requirements and standards. Drug Inform J 1991; 25: 471-82.
[18] Chen ML, Patnaik R, Hauck WW, Schuirmann DJ, Hyslop T, Williams R. An individual bioequivalance criterion: regulatory considerations. Statistics Med 2000; 19: 2821-42.
- Resumen ##plugins.themes.ojsPlusA.frontend.article.viewed##: 72 ##plugins.themes.ojsPlusA.frontend.article.times##
- IJPS_Volume 1_Issue 4_Pages 209-215 (English) ##plugins.themes.ojsPlusA.frontend.article.downloaded##: 58 ##plugins.themes.ojsPlusA.frontend.article.times##